

Connecticut Medicaid P&T Meeting Minutes – September 6, 2007

The meeting started at 6:30 pm

Attendance

Present Members:

Carl Sherter, MD
Peggy Manning Memoli, Pharm D
Joseph Misiak, MD
Robert Zavoski, MD
Steven Marcham, RPh
Lawrence Sobel, RPh
Richard T. Carbray, Jr., RPh
Holly Bessoni-Lutz, RN

DSS:

Evelyn Dudley
Herman Kranc
Jim Zakszewski

EDS/Provider Synergies:

Matt Hosford
Ellen Arce
Joy DeNardo

Absent Members:

Stella Cretella
Kenneth Marcus, MD

Opening remarks:

Dr. Sherter made the following announcements:

Joy DeNardo, RPh, is the new PA/PDL Coordinator for EDS

Approval of minutes:

Committee members approved minutes as submitted from the June 7, 2007 meeting.

Public Presentations:

Dr. Krystn Wagner, Medical Director, Nathan Smith Clinic, Yale School of Medicine/Yale New Haven Hospital addressed the committee regarding the preferred drugs used to treat Hepatitis C.

New Generics:

Matt Hosford informed the Committee members regarding the following new generic products:

- The generic for Lotrel will be non-preferred because of pricing. The brand is currently preferred. We will re-evaluate in 6 months as more generic products are made available.
- The generics for Uniretic and Verelan PM should be listed as preferred.

Committee agreed with all recommended statuses.

Therapeutic Class Reviews:

Matt Hosford, from Provider Synergies, presented clinical data and financial analysis, as well as answered questions from committee members on the following twelve therapeutic classes. Outcomes and votes are recorded below by class:

Hepatitis C Agents

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accepted Provider Synergies' recommendations. The motion was passed unanimously.

ON PDL: Pegasys, Peg-Intron, Peg-Intron Redipen, ribavirin

OFF PDL: Copegus, Infergen, RebetoI

Oral Antifungal Agents

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accept Provider Synergies' recommendations as presented. The motion was passed unanimously.

ON PDL: clotrimazole, fluconazole, griseofulvin susp, Gris-Peg, ketoconazole, nystatin, terbinafine

OFF PDL: Ancobon, Grifulvin V Tablets, itraconazole, Noxafil, Vfend

Topical Antifungal Agents

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accepted Provider Synergies' recommendations as presented. The motion was passed unanimously.

ON PDL: ciclopirox cream & suspension, clotrimazole/betamethasone, Exelderm, ketoconazole (shampoo only), Mentax, Naftin, nystatin, nystatin/triamcinolone, Xolegel

OFF PDL: econazole, Ertaczo, ketoconazole cream, Loprox Gel, Loprox Shampoo, Oxistat, Penlac, Vusion

Antimigraine Agents, Triptans

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accepted Provider Synergies' recommendations as presented. The motion was passed unanimously.

ON PDL: Imitrex (Nasal), Imitrex (Oral), Imitrex (SQ), Relpax

OFF PDL: Amerge, Axert, Frova, Maxalt / Maxalt MLT, Zomig (Nasal), Zomig / Zomig ZMT

Antivirals

Matt Hosford presented the evaluation and recommendation for this class. The committee had concerns with excluding Tamiflu and recommended that it retain its preferred status. The committee motioned to approve and accepted Provider Synergies' recommendations with the addition of Tamiflu. The motion was passed unanimously.

ON PDL: acyclovir, amantadine, rimantadine, Tamiflu, Valtrex

OFF PDL: Famvir, Relenza

Bladder Relaxants

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accepted Provider Synergies' recommendations as presented. The motion was passed unanimously.

ON PDL: Detrol / Detrol LA, Enablex, oxybutynin (not XL), Oxytrol, Sanctura, Vesicare

OFF PDL: Oxybutynin ER

BPH Treatments

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accepted Provider Synergies' recommendations as presented. The motion was passed unanimously.

ON PDL: Avodart, doxazosin, finasteride, Flomax, terazosin, Uroxatral

OFF PDL: Cardura XL

Cephalosporins and Related

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accepted Provider Synergies' recommendations as presented. The motion was passed unanimously.

ON PDL: amoxicillin/clavulanate, Cedax, cefaclor, cefdinir, cefprozil, cefuroxime, cephalexin, Spectracef, Suprax

OFF PDL: Augmentin XR, cefadroxil, cefpodoxime, Raniclur

Fluoroquinolones, Oral

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accepted Provider Synergies' recommendations as presented. The motion was passed unanimously.

ON PDL: Avelox, ciprofloxacin tablets, ofloxacin

OFF PDL: Cipro Suspension, Ciprofloxacin ER, Factive, Levaquin, Noroxin, Proquin XR

Glucocorticoids, Inhaled

Matt Hosford presented the evaluation and recommendation for this class. The committee questioned if the Pulmicort Flexhaler market share data was accurate and would have also liked to review the utilization for the Turbohaler which preceded the Flexhaler. Furthermore, several committee members had concerns with excluding Pulmicort and recommended that Pulimort Flexhaler be added to the preferred list. The committee motioned to approve and accepted Provider Synergies' recommendations with the addition of Pulmicort Flexhaler. The motion was passed unanimously.

ON PDL: Advair Diskus / Advair HFA, Aerobid / Aerobid-M, Asmanex, Azmacort, Flovent / Flovent HFA, Pulmicort Flexhaler, Qvar

OFF PDL: Pulmicort Respules, Symbicort

Hypoglycemics, Incretin Mimetics

Matt Hosford presented the evaluation and recommendation for this class. The committee members had concerns with excluding Januvia and Janumet and recommended adding both drugs to the preferred list. The committee motioned to approve adding Januvia and Janumet to the preferred drug list. The motion was passed unanimously.

** Note: Byetta and Symlin were already on the PDL but were moved to this class from *Hypoglycemics, Insulin & Related* although they were not voted on at this P & T meeting**

ON PDL: Byetta, Janumet, Januvia, Symlin

OFF PDL: None

Hypoglycemics, Meglitinides

Matt Hosford presented the evaluation and recommendation for this class. The committee motioned to approve and accepted Provider Synergies' recommendations as presented. The motion was passed unanimously.

ON PDL: Prandin, Starlix

OFF PDL: None

Macrolides and Ketolides

Matt Hosford presented the evaluation and recommendation for this class. The committee members had concerns with excluding both forms of clarithromycin and recommended that the generic clarithromycin (not the XL) be added to the preferred list. The committee motioned to approve and accepted Provider Synergies' recommendations with the addition of clarithromycin. The motion was passed unanimously.

ON PDL: azithromycin, clarithromycin (not XL), erythromycin

OFF PDL: Biaxin XL, Ketek, Zmax

Recommendations for next class reviews:

Provider Synergies recommended the following classes be reviewed at the next P&T meeting:

- Angiotensin Modulators/CCB Combinations
- Bronchodilators, Anticholinergic
- Bronchodilators, Beta Agonist
- Hypoglycemics, Insulins
- Leukotriene Modifiers
- Ophthalmics, Allergic Conjunctivitis
- Ophthalmics, Fluoroquinolones
- Ophthalmics, Glaucoma
- Phosphate Binders
- Platelet Aggregation Inhibitors
- Ulcerative Colitis Agents

The committee asked that EDS contact Dr. Vincent DeLuise for clinical feedback and professional opinions for the review of Ophthalmic agents for the December 6, 2007 meeting.

Schedule next meeting:

Committee members agreed on Thursday, December 6, 2007 for the next P&T meeting.

Meeting adjourned at 7:07pm